LogicBio Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases.

GeneRide™ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies

With GeneRide™, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.

LogicBio has been acquired by Alexion, AstraZeneca Rare Disease. For future updates on our genome editing program, follow Alexion Pharmaceuticals.

✕

Access Insights for LogicBio Therapeutics and Millions of Other Companies

Sign up for full access to LogicBio Therapeutics information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory